Cortiva与AlloDerm在胸肌前及部分胸肌下假体乳房重建中的比较:一项随机临床试验
该单盲随机对照试验在2家学术医院比较Cortiva与AlloDerm在即刻假体乳房重建中的表现,共纳入302例患者(AlloDerm组151例280侧乳房,Cortiva组151例277侧乳房)。两组重建失败率无差异(AlloDerm 9.3% vs Cortiva 8.3%,P=0.68),其他并发症及患者报告结局亦无差异;Cortiva组血清肿发生率低于AlloDerm组(7.6% vs 12%),AlloDerm血清肿形成风险约为Cortiva的1.93倍(OR 1.93,95%CI 1.01-3.67,P=0.047),且AlloDerm可变成本比Cortiva高10%至15%。结论认为Cortiva在安全性、临床性能、患者报告结局及成本方面非劣于AlloDerm,且可能更便宜、血清肿风险更低。
要点
- 两组重建失败率无差异:AlloDerm 9.3% vs Cortiva 8.3%,P=0.68。
- Cortiva组血清肿发生率7.6%,低于AlloDerm组的12%,AlloDerm血清肿风险OR 1.93(95%CI 1.01-3.67)。
- AlloDerm可变成本比Cortiva高10%至15%,其他成本无差异。
核心结论
- 在安全性、临床性能、患者报告结局及成本方面,Cortiva在即刻假体乳房重建中非劣于AlloDerm,且可能更便宜、血清肿形成风险更低。
研究设计与样本
- 单盲随机对照试验,于2017年3月至2021年12月在2家学术医院开展,比较Cortiva与AlloDerm在胸肌前及胸肌下即刻假体乳房重建中的应用。
- 重建方式为直接置入假体(DTI)或组织扩张器(TE),共纳入302例患者:AlloDerm组151例(280侧乳房),Cortiva组151例(277侧乳房)。
- 主要结局为重建失败,定义为TE在计划进一步重建前取出,或DTI重建在术后3个月前取出;次要结局为其他并发症、患者报告结局(PROs)及成本。
主要发现
- 两组重建失败率无差异:AlloDerm 9.3% vs Cortiva 8.3%,P=0.68。
- 两组在其余任何并发症或患者报告结局方面均无额外差异。
- Cortiva组血清肿发生率为7.6%,AlloDerm组为12%,AlloDerm组血清肿形成风险约为Cortiva组的1.93倍(OR 1.93,95%CI 1.01-3.67,P=0.047)。
- AlloDerm可变成本比Cortiva高10%至15%,其他成本无差异。
关键数值与推荐
- 重建失败定义:TE在计划进一步重建前取出,或DTI重建在术后3个月前取出。
- 证据等级:治疗性,I级。
临床怎么用
- 原文结论认为Cortiva在即刻假体乳房重建中非劣于AlloDerm,且可能更便宜、血清肿风险更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several acellular dermal matrices (ADMs) are used for soft-tissue support in prosthetic breast reconstruction. Little high-level evidence supports the use of one ADM over another. The authors sought to compare Cortiva 1-mm Allograft Dermis with AlloDerm RTU (ready to use), the most studied ADM in the literature. METHODS: A single-blinded randomized controlled trial comparing Cortiva with AlloDerm in prepectoral and subpectoral immediate prosthetic breast reconstruction was performed at 2 academic hospitals from March of 2017 to December of 2021. Reconstructions were direct to implant (DTI) or tissue expander (TE). Primary outcome was reconstructive failure, defined as TE explantation before planned further reconstruction, or explantation of DTI reconstructions before 3 months postoperatively. Secondary outcomes were additional complications, patient-reported outcomes (PROs), and cost. RESULTS: There were 302 patients included: 151 AlloDerm (280 breasts), 151 Cortiva (277 breasts). The majority of reconstructions in both cohorts consisted of TE (62% versus 38% DTI), smooth device (68% versus 32% textured), and prepectoral (80% versus 20% subpectoral). Reconstructive failure was no different between ADMs (AlloDerm 9.3% versus Cortiva 8.3%; P = 0.68). There were no additional differences in any complications or PROs between ADMs. Seromas occurred in 7.6% of Cortiva but 12% of AlloDerm cases, in which the odds of seroma formation were two-fold higher (odds ratio, 1.93 [95% CI, 1.01 to 3.67]; P = 0.047). AlloDerm variable cost was 10% to 15% more than Cortiva, and there were no additional cost differences. CONCLUSION: When assessing safety, clinical performance, PROs, and cost, Cortiva is noninferior to AlloDerm in immediate prosthetic breast reconstruction, and may be less expensive, with lower risk of seroma formation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I.
引用
- Keane AM, Chiang SN, Tao Y, et al. Cortiva versus AlloDerm in Prepectoral and Partial Submuscular Implant-Based Breast Reconstruction: A Randomized Clinical Trial. Plast Reconstr Surg. 2024. PMID: 38085977. doi:10.1097/PRS.0000000000011244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。